Insider Trading April 16, 2026 05:54 PM

Westwood Holdings Director Emerita Sells 2,301 Shares in Three-Day Sequence

Susan M Byrne disposes $37,709 in WHG stock under a 10b5-1 plan; company reports Q4 2025 revenue and net income growth tied to ETF offerings

By Caleb Monroe WHG
Westwood Holdings Director Emerita Sells 2,301 Shares in Three-Day Sequence
WHG

Susan M Byrne, director emerita of Westwood Holdings Group Inc (NYSE: WHG), sold 2,301 shares of the company's common stock across April 14-16, 2026, for total proceeds of $37,709 under a Rule 10b5-1 trading plan adopted on April 1, 2026. Following the transactions Byrne holds 296,744 shares. Separately, Westwood reported Q4 2025 revenue of $27.1 million, up from $25.6 million year-over-year, with growth attributed to its ETF products and notable year-over-year net income gains; the stock declined 0.34% after the report.

Key Points

  • Director emerita Susan M Byrne sold 2,301 shares of Westwood Holdings (WHG) across April 14-16, 2026, generating $37,709 in proceeds.
  • The trades executed at a weighted average price range of $16.1382 to $16.4813 and were conducted under a Rule 10b5-1 plan adopted on April 1, 2026.
  • Westwood reported Q4 2025 revenue of $27.1 million, up from $25.6 million year-over-year, driven by ETF product performance; net income also grew significantly year-over-year, while the stock fell 0.34% after the report.

Susan M Byrne, who serves as director emerita at Westwood Holdings Group Inc (NYSE: WHG), executed a set of stock sales over three consecutive trading days in mid-April 2026, according to a Form 4 filed with the Securities and Exchange Commission.

The filing shows Byrne sold a total of 2,301 shares of Westwood common stock on April 14, April 15 and April 16, 2026. The individual transactions were: 301 shares on April 14; 1,500 shares on April 15; and 500 shares on April 16. The aggregate proceeds from those sales amounted to $37,709. The trades occurred at a weighted average price per share that ranged from $16.1382 to $16.4813.

Following completion of these dispositions, Byrne directly owns 296,744 shares of Westwood Holdings Group Inc.

The sales were carried out under a pre-established Rule 10b5-1 trading plan that Byrne adopted on April 1, 2026. The Form 4 indicates the transactions were executed pursuant to that plan.


In related company disclosures, Westwood Holdings reported year-over-year revenue growth for the fourth quarter of fiscal 2025. Total revenues for Q4 2025 were $27.1 million, up from $25.6 million in the same quarter a year earlier. The company attributed the revenue increase to strong performance in its ETF products. The firm also recorded significant year-over-year growth in net income for the quarter.

Despite those positive financial results, Westwood's stock price registered a modest decline of 0.34% following the earnings report. The companys recent financials and Byrnes planned sales are likely to remain points of interest for market participants monitoring Westwood's trajectory, though the filing does not provide any commentary beyond the mechanics of the trades and the plan under which they occurred.

Where the public filings offer limited detail, the records are explicit about dates, quantities, proceeds and the origin of the trades. The Form 4 documents the transactions and the 10b5-1 plan adoption date of April 1, 2026, while the company's earnings disclosure provides the revenue and net income figures and the modest post-report share price movement.

Risks

  • The Form 4 provides transactional details but does not explain the motivations behind the sales - this limits interpretability for investors assessing insider sentiment.
  • Although Westwood reported revenue and net income growth for Q4 2025, the company's stock still experienced a modest decline of 0.34% after the report, indicating potential short-term market sensitivity.
  • Information in the filings and the earnings disclosure is specific to the stated periods and amounts; lacking further forward-looking detail creates uncertainty about near-term operational trajectory.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026